Latest news with #Chun-Hsien(Eddy)Tsai
Associated Press
5 days ago
- Business
- Associated Press
Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80%
Accelerating Toward Commercial Rollout as AI Nose Solves Critical Gaps in Elder Care SAN DIEGO, CA / ACCESS Newswire / May 29, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ('Ainos'), a leader in AI-powered scent digitization, announced today that its proprietary AI Nose platform achieved approximately 85% accuracy in detecting excretion odors data, an improvement from 80% previously, based on collected from 254 participant instances in Japan and Taiwan, resulting in 2119 valid entries for subsequent statistical evaluation. The milestone validates AI Nose as a deploy able solution for non-contact hygiene monitoring in long-term care (LTC) and positions Ainos to lead the emerging SmellTech category. SmellTech for Digitized, AI-Powered Long-term Care AI Nose digitizes scent into Smell IDs using MEMS gas sensors and proprietary AI models harnessing 13 years of scent data across healthcare and industrial use-cases. Its compact, embedded-ready design enables seamless integration into portable devices, ambient monitors, or robotic platforms. Ainos is aiming to address the aging population by aligning with government efforts to digitize aging care and reduce institutional burden. Ainos targets high-impact use cases in long-term care for seniors, including: Japan and Taiwan Face Alarming Demographic Pressure Japan and Taiwan are doubling down on robotic and AI-assisted care through initiatives like Society 5.0, Healthcare DX, and Taiwan's Long-Term Care 2.0. Ainos' AI Nose aims to support these national priorities by delivering precision, automation, and labor cost relief. Commercial Rollout Timeline Ainos is also partnering with Japan's leading service robotics company to embed AI Nose into autonomous robots, bringing olfaction into smart care infrastructure for the first time. SmellTech: A $76.5B Opportunity by 2032 Ainos is pioneering SmellTech as a new category of machine perception. The global electronic nose market is forecast to grow from $29.8B in 2025 to $76.5B by 2032, at a 14.4% CAGR, with growing use in healthcare. With solid validation, real-world deployment in progress, and deep IP, Ainos is positioned to capture first-mover advantage in this rapidly scaling sector. Human-Centric Vision and Corporate Responsibility 'I believe AI Nose is a new sensory layer for healthcare,' said Chun-Hsien (Eddy) Tsai, Chairman, President and CEO of Ainos. 'We design this platform to meet real human needs: protecting dignity, reducing labor pressure, and enabling smarter aging care. With Japan and Taiwan both facing demographic cliffs, this milestone proves that smell-driven automation can be a game-changer.' While Ainos pursues innovation and commercialization, the development of its bio-inspired electronic nose technology is fundamentally guided by a humanitarian mission. The company is dedicated to enhancing the quality of life for the elderly, alleviating long-term societal care burdens, and promoting dignity and harmony within caregiving environments and families. 'We may be a technology company, but our purpose is deeply human,' said Tsai. 'AI Nose represents more than a breakthrough in digital scent-it's Ainos' promise to confront the aging crisis with compassion and to protect the dignity of those we love.' About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit Follow Ainos on X, formerly known as Twitter, ( @AinosInc ) and LinkedIn to stay up-to-date. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shen [email protected] SOURCE: Ainos, Inc. press release
Associated Press
14-04-2025
- Business
- Associated Press
Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan
Dual Trials Accelerate VELDONA® Toward Rare Disease Market Entry Bridging Strategy Aims to Fast-Track U.S. Regulatory Approvals SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 14, 2025 / Ainos, Inc. (Nasdaq:AIMD, AIMDW) ('Ainos' or the 'Company'), pioneer of low-dose oral interferon therapeutics, today announced significant progress in advancing its oral interferon drug platform, VELDONA® in the rare disease space. The Taiwan Food and Drug Administration (TFDA) has approved the Company's clinical trial for human immunodeficiency virus (HIV)-related oral warts, while Institutional Review Board (IRB) clearance has been granted for its upcoming Sjögren's Syndrome (pSS) study. The upcoming Taiwan trials will be conducted using the Company's next-generation VELDONA® formulation, aiming to confirm efficacy equal to or better than previous results, as well as accelerating US and Taiwan regulatory approval and commercialization. 'The upcoming Taiwan trials using our new formulation aim to confirm efficacy equal to or better than previous results. We are also pursuing bridging consultations with both Food and Drug Administration (FDA) and TFDA. If regulators confirm alignment, we could accelerate market entry through a harmonized approval process. Our partnership with Taiwan Tanabe Seiyaku for manufacturing and market development of our pSS program further strengthens our commercialization pathway,' said Chun-Hsien (Eddy) Tsai, Chairman, President, and CEO of Ainos. 'Ainos is steadily advancing across three core growth pillars: scent digitization with AI Nose technology, AI-powered point-of-care testing powered by AI Nose, and VELDONA®. These strategic pillars form a foundation to our growth. We're executing rapidly and building momentum across the VELDONA® platform. Our ability to launch two Taiwan trials in parallel reflects our dedication to capital efficiency, operational strength and delivering innovative, patient-friendly therapies to the market,' Mr. Tsai added. 'HIV-related oral warts and primary Sjögren's Syndrome both lack effective standard treatments and impose meaningful burdens on quality of life. As an oral therapy, VELDONA® provides a convenient, non-invasive alternative to injectable interferons-especially important for chronic or immune-compromised patients. We believe our previous Phase II and III trials delivered positive results, and we see significant potential for VELDONA® in these indications,' said Dr. Albert Yu, Technical Director of Pharmaceuticals at Ainos. These studies expand Ainos' immunotherapy footprint in underserved rare disease segments, in line with the Company's previously announced development plans. TFDA Approves HIV Oral Warts Trial; Enrollment to Begin in June Ainos' planned trial, titled 'Evaluation of Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-Seropositive Subjects Receiving Combination Anti-Retroviral Therapy' (Protocol ID: 03HUHI19), will be conducted at National Taiwan University Hospital (NTUH). Oral warts are a frequent and painful complication in HIV-positive patients. According to UNAIDS, approximately 39.9 million people globally live with HIV in 2023, with 1.3 million new infections and 630,000 AIDS-related deaths reported that year. Despite prevalence, oral wart treatment remains a poorly addressed niche with limited therapeutic options. The market for managing HIV-related HPV manifestations, including oral warts, is estimated at $500-700 million globally, driven by demand for safer and more tolerable long-term treatments1. Ainos plans to begin the trial in June 2025 and targets completion in 2H 2026. Primary and secondary endpoints will evaluate the efficacy of VELDONA® plus antiretroviral therapy compared to placebo. Bestat Pharmaservices Corporation, a TFDA-accredited contract research organization (CRO), will manage the study under Good Clinical Practice (GCP) standards. IRB Clears Sjögren's Syndrome Trial; TFDA Review in Progress The planned trial, titled 'An Open-Label Study to Evaluate the Efficacy Of VELDONA® in Patients with Primary Sjögren's Syndrome' (Protocol ID: 24PSS01) received IRB approval from Taipei Medical University - Joint IRB on October 25, 2024 (Approval No.: TMU-JIRB N202408042). TFDA submission is underway, with clearance expected in August 2025. Sjögren's Syndrome is a chronic autoimmune disease affecting salivary and tear glands, with limited treatment options. According to National Center for Biotechnology Information (NCBI), the condition affects an estimated 400,000 to 3.1 million people in the U.S. alone, mostly women aged 45-55. The global market for Sjögren's Syndrome therapeutics is projected to reach about $3.3 billion by 2030, driven by rising prevalence and increasing demand for effective therapies2. The trial will take place at Shuang Ho Hospital and evaluate whether VELDONA® improves salivary flow and alleviates dryness symptoms. Secondary endpoints include ESSPRI/ESSDAI scores, symptom-specific VAS ratings, and salivary gland imaging. Ainos aims to initiate site initiation visit (SIV) and first patient first visit (FPFV) in October 2025 and targets to conclude the trial in 1H 2027. ComboTrial Consultancy Ltd, a TFDA-recognized CRO, will manage the trial. Ainos has previously completed three U.S. clinical trials evaluating VELDONA® in pSS. Results showed significant improvement in oral dryness with a favorable safety profile. VELDONA®: Transforming Immunotherapy Through Oral Delivery Harnessing nearly four decades of development, VELDONA® is Ainos' proprietary low-dose oral interferon-alpha platform, designed to activate immune responses via oromucosal delivery. The platform delivers therapeutic benefit at ultra-low doses, minimizing systemic side effects often associated with injectable interferons. By targeting rare and underserved indications, Ainos is positioning VELDONA® as a versatile, scalable solution for chronic autoimmune and infectious diseases across global markets. [1]: Market scope estimate based on various analysis of HPV/HIV co-infection treatment segments. [2]: Market Report Analytics, 'Sjogrens Syndrome Therapeutics Market CAGR Growth Drivers and Trends: Forecasts 2025-2033.' About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify Ainos' commitment to enabling AI with the ability to smell and individuals to live healthier. Ainos' clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. For more information, visit: Follow Ainos on X, formerly known as Twitter, ( @AinosInc ) and LinkedIn to stay up-to-date. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shen [email protected] SOURCE: Ainos, Inc. press release
Yahoo
05-03-2025
- Business
- Yahoo
Ainos and ugo to Develop the World's First Robot With a Sense of Smell
A Major Breakthrough in Ainos' Mission to Digitize Scent First-ever Smell-Enabled Robotics Will Unlock New Revenue Streams in Smart Manufacturing, Public Safety and more SAN DIEGO, CA / / March 5, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW), a pioneer of smell digitization, and ugo, Inc., Japan's largest service robot company by market share1, today announced a strategic partnership to integrate Ainos' AI Nose technology with ugo's autonomous robotic platform. This collaboration will mark a major milestone in the digitization of smell, unlocking new capabilities for robots in industrial safety, healthcare, and public security. AI Nose, originally developed for medical diagnostics, mimics human olfaction by detecting and analyzing volatile organic compounds (VOCs). Backed by nearly a decade of research and a strong patent portfolio, AI Nose has already demonstrated its effectiveness in healthcare and industrial environments. In Japanese semiconductor manufacturing facilities, AI Nose has successfully identified 22 different VOCs with nearly 80% accuracy, proving its potential to enhance real-time safety monitoring and environmental analysis. Pioneering a Breakthrough: Giving Robots the Power to Smell Until now, robots have relied primarily on vision, sound, and touch to perceive their surroundings. Smell has remained an unsolved technological challenge-but Ainos is about to change that. With the integration of AI Nose, ugo robots will gain olfactory perception, enabling them to: Enhance Industrial Safety: Detect gas leaks, identify toxic chemicals, and prevent equipment failures in semiconductor, chemical, and manufacturing plants. Strengthen Public Safety: Assist in security patrols by detecting explosives, narcotics, and hazardous substances in transportation hubs and critical infrastructure. Advance Environmental Monitoring: Provide continuous air quality assessments, detect pollutants, and support smart city initiatives. Transform Healthcare: Analyze VOC samples for early disease detection, support infection control in hospitals, and monitor elderly care facilities for hygiene and health risks. "This partnership will be a defining moment in our journey to digitize smell," said Chun-Hsien (Eddy) Tsai, Chairman, President and CEO of Ainos. "By combining AI Nose's cutting-edge olfactory sensing with ugo's advanced robotics, we will create a new category of intelligent machines that can see, hear, and now-smell." Ken Matsui, Representative Director of ugo, added, "Olfaction is the next frontier in robotics. Integrating AI Nose into our robots will significantly expand their sensory intelligence, making them more effective in real-world applications across industries. Our robots, including ugo Pro, ugo Ex and ugo mini, are deployed in Japanese sectors facing worker shortages, such as security patrols and inspection tasks, in office buildings, data centers, manufacturing plants, and public facilities. By equipping ugo robots with AI-driven scent detection, we are taking automation to the next level-providing intelligent solutions that improve workplace safety, environmental monitoring, and healthcare support." Exploring the Future of Robotics with AI-Powered Scent Detection By exploring the integration of AI Nose into ugo's robotic platform, there is potential to create new revenue opportunities through various business models: Technology Licensing & Hardware Sales: Ainos will license AI Nose technology to ugo, enabling ugo to offer premium olfaction-enabled robots. Robotics-as-a-Service (RaaS): Businesses can deploy AI Nose-equipped ugo robots through subscription-based models for continuous air monitoring and safety inspections. Cloud-Based Scent Intelligence: AI Nose-generated data will be integrated into cloud analytics platforms, offering insights for smart factories, healthcare, and security applications. Maintenance & Sensor Optimization: Ongoing servicing, software updates, and sensor calibration will ensure long-term reliability and accuracy. From Concept to Reality: The Roadmap to a Smarter Robot This collaboration will advance through a structured development plan designed to bring AI-powered olfaction to robotics: Seamless Technology Integration & Prototyping: Ainos and ugo will merge AI Nose with ugo robots and conduct initial performance testing. Real-World Pilot Deployments: The companies will validate the integrated solution in industries such as semiconductor manufacturing and public safety. AI Optimization & Performance Enhancement: System performance and AI models will be refined based on real-world data. Global Commercialization & Market Expansion: Ainos and ugo will scale the deployment of AI Nose-enabled robots worldwide. Empowering Industries and Addressing Labor Shortages with Intelligent Automation Beyond its commercial value, this collaboration will help address one of the most pressing challenges faced by industries worldwide: the growing labor shortage in critical sectors. Manufacturing & Industrial Safety: Skilled workers are increasingly difficult to find, and ensuring workplace safety remains a top priority. AI Nose-equipped ugo robots will take on hazardous inspection tasks, reducing risks and allowing human workers to focus on higher-value roles. Security & Public Safety: From airports to industrial sites, there is an increasing need for security personnel to handle safety threats. AI Nose-integrated robots will provide continuous, automated surveillance, enhancing security operations without additional staffing burdens. Healthcare & Elderly Care: The demand for healthcare services is surging due to aging populations, while shortages of medical and caregiving staff continue to grow. AI Nose-enabled robots will assist in monitoring patient health, detecting infections early, and supporting hygiene management in hospitals and elderly care facilities. By combining AI-powered scent detection with autonomous robotics, Ainos and ugo will help industries improve efficiency, reduce operational costs, and enhance workplace safety-while addressing the global labor gap. As the world faces increasing challenges in workforce shortages, sustainability, and public safety, this partnership will contribute to a smarter, healthier, and safer future. Ainos and ugo are committed to driving innovation that improves lives and supports industries in need of intelligent automation. About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name "Ainos" combines "AI" and "Nose" to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date. About ugo, Inc. ugo, Inc. is a developer of business digital transformation robots. "ugo" is a next-generation avatar robot that realizes a sustainable work style with humans and robots. By combining the advantages of both conventional simple remote-controlled robots and fully automated robots, it provides operations that fit the site. ugo was founded in 2018 and headquartered in Tokyo, Japan. For more information, visit website or its X (@ugo_robot). Keizai Group's "2024 Edition: Current Status and Future Prospects of the Worldwide Robot-Related Market - Service Robot Edition" published on January 15, 2024. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. Contact Information Feifei Shenir@ SOURCE: Ainos, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Associated Press
27-01-2025
- Business
- Associated Press
Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
Revolutionary Oral Interferon Technology Combines Unmatched Advantages and Global Potential in the $16 Billion Coronavirus Market SAN DIEGO, CA / ACCESS Newswire / January 27, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ('Ainos' or the 'Company') proudly announces the granting of a pivotal invention patent in Japan (Patent No. 7619659) for its groundbreaking oral interferon formulation, VELDONA®, to treat and prevent coronavirus infections. Following the recent patent approval in Taiwan, this Japanese patent strengthens Ainos' global intellectual property (IP) portfolio and establishes the Company as a leader in differentiated antiviral solutions. The global coronavirus therapeutics market is projected to exceed $16 billion by 2031. With its patented sublingual interferon technology, Ainos is poised to redefine antiviral treatment standards, offering a cost-effective, scalable, and patient-friendly alternative to traditional therapies. Key Patent Highlights and Technical Innovations The newly granted patent includes 15 key claims that deliver comprehensive protection for VELDONA®, covering its formulation, novel sublingual and buccal delivery mechanisms, and broad therapeutic applications. The patented features emphasize: • Low-Dose Administration: Using doses under 1,000 IU to optimize efficacy and minimize side effects. • Innovative Delivery Mechanisms: Sublingual and buccal absorption for rapid action and enhanced bioavailability, eliminating the need for injections. • Flexible Dosage Forms: Includes lozenges, tablets, films, and sprays, offering greater convenience for patients. • No Cold Chain Requirements: Unlike traditional interferon therapies that rely on costly cold chain logistics, VELDONA®'s oral formulation significantly reduces logistical and operational costs. 'This patent represents a significant breakthrough for interferon-based therapies. With patents already granted in Taiwan and Japan, and additional applications underway in other countries, we are reinforcing our global IP portfolio and advancing our commercialization strategy in a multi-billion-dollar market,' said Chun-Hsien (Eddy) Tsai, Chairman and CEO of Ainos. A Differentiated Solution for a Persistent Challenge As coronavirus continues to mutate and pose long-term threats to global health, VELDONA® offers dual benefits: 1. Treatment: Proven broad-spectrum antiviral efficacy against multiple coronavirus variants. 2. Prevention: Potential to strengthen immune defenses and reduce susceptibility to new infections. VELDONA® addresses critical gaps in current treatment options, including: • Accessibility: A patient-friendly, non-invasive oral therapy. • Affordability: Eliminates the dependency on expensive cold chain logistics, ensuring cost-effective global distribution. • Safety: A low-dose formulation with minimal side effects compared to traditional interferon treatments. 'With VELDONA®, we're setting a new standard for innovation in antiviral therapies,' added Tsai. 'Our solution combines cutting-edge science with practical advantages, offering a competitive edge that positions Ainos as a global leader in antiviral innovation.' Expanding Beyond Coronavirus Beyond its role in addressing coronavirus infections, VELDONA® has demonstrated potential applications across a wide range of immune-related conditions, including autoimmune diseases, and other viral infections. Its flexibility and adaptability highlight its potential to transform therapeutic approaches in multiple medical fields. Ainos' Vision for Global Health With nearly 40 years of research and development, Ainos has consistently driven innovation in antiviral technologies. VELDONA® exemplifies the Company's commitment to delivering differentiated, cost-effective solutions that address critical public health challenges. Dr. Albert Yu, Technical Director of Pharmaceuticals at Ainos, remarked: 'This patent is not just a validation of our innovation but also a significant milestone in our journey to combat global health threats. We look forward to VELDONA®'s broad clinical applications and its ability to benefit patients worldwide.' Ainos asserts that the coronavirus will persist as a long-term global health challenge. The Company is committed to providing accessible, scalable solutions to protect human health, mitigate the virus's impact, and improve global immunity. With its high efficacy, minimal side effects, and scalable design, VELDONA® is positioned as the next-generation antiviral solution. Ainos will continue to advance antiviral technologies and set new benchmarks in global health innovation About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. develops disruptive medical and healthcare solutions based on its proprietary AI Nose and VELDONA® technologies. The name 'Ainos' combines 'AI' and 'Nose' to signify the Company's commitment to enabling AI with the ability to smell and individuals to live healthier. The Company's clinical-stage product pipeline includes AI-driven, telehealth-friendly POCT solutions powered by AI Nose, VELDONA® human and animal oral therapeutics, and human orphan drugs. To learn more, visit Follow Ainos on X, formerly known as Twitter, ( @AinosInc) and LinkedIn to stay up-to-date. Safe Harbor Statement Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by the use of words such as 'anticipate,' 'believe,' 'estimate,' 'approximate,' 'expect,' 'intend,' 'plan,' 'predict,' 'project,' 'target,' 'future,' 'likely,' 'strategy,' 'foresee,' 'may,' 'guidance,' 'potential,' 'outlook,' 'forecast,' 'should,' 'will' or other similar words or phrases. Similarly, statements that describe the Company's objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company's current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results may differ materially from those indicated in the forward-looking statements. Important factors that could cause the Company's actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the products announced in this press release; the Company's dependence on projected revenues from the sale of current or future products; the Company's limited cash and history of losses; the Company's ability to achieve profitability; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos' product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the accuracy of third-party market research data, the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; continued listing on and compliance with the applicable regulations of the Nasdaq Capital Market; and the Company's success in managing growth. A more complete description of these risk factors and others is included in the 'Risk Factors' section of Ainos' Annual Report on Form 10-K for the year ended December 31, 2023, and other public filings with the U.S. Securities and Exchange Commission ('SEC'), many of which risks are beyond the Company's control. In addition to the risks described above and in the Company's filings with the SEC, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release. The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Any forward-looking statements contained in this press release represent Ainos' views only as of today and should not be relied upon as representing its views as of any subsequent date. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.
